Cancer Screening Companies Are Rapidly Proliferating: Are They Ready for Business?

Article Medical Laboratory Technology

Sensitive Blood-Based Detection of Asbestos- Associated Diseases Using Cysteine-Rich Angiogenic Inducer 61 as Circulating Protein Biomarker

Kai Bartkowiak et al.

Summary: The study showed that plasma Cyr61 protein concentrations could be a new biomarker for asbestos-associated diseases like BAAD and mesothelioma in men, which warrants further investigation in large-scale cohort studies.

CLINICAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

Liquid biopsy enters the clinic - implementation issues and future challenges

Michail Ignatiadis et al.

Summary: The approval of liquid biopsy assays for detecting genetic alterations in plasma cell-free DNA has marked a tipping point for the clinical use of this technology, especially in patients with advanced-stage cancer. The next frontier is likely to be the systemic treatment of patients with 'ctDNA relapse' and other potential future applications include cancer screening and diagnosis.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

The IARC Perspective on Cervical Cancer Screening

Veronique Bouvard et al.

Summary: This article reviews the best methods of screening for cervical cancer, with HPV nucleic acid testing being superior whether used alone or in combination with other methods.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Medical Laboratory Technology

Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?

Michael J. Duffy et al.

Summary: Early detection of cancer through pan-cancer screening tests using ctDNA shows promising high specificity (>99%) but varying sensitivity based on cancer type and stage. Clinical utility still needs to be demonstrated through prospective randomized screening trials to show reduced mortality.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)

添加到收藏夹

Article Oncology

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

E. A. Klein et al.

Summary: This study confirmed the feasibility of using the refined MCED test version as a screening tool, demonstrating high specificity and accuracy in predicting CSO, and detecting signals of various cancers.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA

Xiaoji Chen et al.

Summary: The study evaluated the prognostic significance of cancer detection by the MCED test using longitudinal follow-up data, finding that cancers detected by the test had lower overall survival rates and could differentiate more aggressive cancers. Cancers not detected by the test had better prognosis, and the MCED test results were predictive of their outcomes.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical correlates of circulating cell-free DNA tumor fraction

Joerg Bredno et al.

Summary: Analysis of circulating tumor DNA in oncology applications is limited by the amount of circulating tumor DNA and the fraction of cell-free DNA derived from tumor cells in a blood sample. Linear models revealed that tumor mitotic volume, excessive lesion glycolysis, and tumor invasion depth are significant correlates of circulating tumor fraction. The identified correlates suggest that faster growing tumors have higher fractions of circulating tumor DNA.

PLOS ONE (2021)

添加到收藏夹

Article Oncology